Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Brightpath Biotherapeutics Co., Ltd.

Clinical trials sponsored by Brightpath Biotherapeutics Co., Ltd., explained in plain language.

BrightPath Biotherapeutics Co., Ltd. 4594 TOKYO

A Japanese biopharmaceutical company developing cell therapies and cancer vaccines.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Not yet recruiting 1

New hope for tough myeloma: early trial of BP2202 begins

Disease control Not yet recruiting

This early-stage trial is testing a new drug called BP2202 in 24 people with multiple myeloma that has come back or no longer responds to standard treatments. The main goal is to see if BP2202 is safe and to find the best dose. Researchers will also watch for any signs that the d…

Phase: PHASE1 • Sponsor: BrightPath Biotherapeutics Co., Ltd. • Aim: Disease control

Last updated Aug 12, 2026 00:00 UTC